Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 5 6 Next >
News headline image
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma 2023 Financial Calendar
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Reports First Half 2022 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma SA
Via Business Wire
Tickers IPHA
News headline image
Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.